article thumbnail

Intersection of Intellectual Property Law and Competition Law with respect to Cross Licensing Agreements

IIPRD

This has led to the introduction of intellectual property rights which are a set of exclusionary rights as it excludes the world from enjoying a set of rights arising out an invention or creation, except the inventor or creator. Cross-licensing agreements can both restrain and advance competition.

article thumbnail

Discretionary Remedies Clarified, and Videotron Ltd Successfully Defends Against Much Litigation-Experienced Rovi Guides Inc.

IPilogue

Rovi’s revenue model is to license a portfolio for a rate without consideration for the number of patents. Videotron did not renew its license which expired in 2016. Videotron claimed they licensed to avoid litigation, and later realized that Rovi’s portfolio is obsolete. Rovi’s conduct. Videotron’s Conduct.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Join the Livestream: How A.I. and Tech are Affecting IP Licensing and Value + “Reaching A New Generation of Inventors”

IP Close Up

Four IP licensing experts will discuss recent changes in the intellectual property licensing landscape, including generative A.I., and how they are affecting innovation. The all-star Continue reading

article thumbnail

New IP Monetization Models Will Rely Less on Litigation in 2022

IP Watchdog

In the decade since the America Invents Act (AIA) was enacted, patent licensing challenges have increased for many technology companies and independent inventors. IP business models will evolve, and risk and return calculations will become more reliable. grants for the first half of 2021.

IP 119
article thumbnail

District Court Grants Summary Judgment and Invalidates Patent in REGENXBIO v. Sarepta Litigation

LexBlog IP

On January 5, 2024, in litigation between REGENXBIO and Sarepta Therapeutics, Judge Richard Andrews of the U.S. 10,526,617 (the ’617 Patent; licensed to REGENXBIO) is invalid as being directed to ineligible subject matter. Sarepta Litigation appeared first on Big Molecule Watch. § 101. Stay tuned.

article thumbnail

The Handwriting is on the IP Wall: Inventors and Content Creators are in the Same Sinking Boat

IP Close Up

When it comes to declining respect for intellectual property rights inventors and content creators, such as photographers, musicians and writers, as well as some trademark Continue reading

article thumbnail

A Lone J&J Inventor is Responsible for $14 Billion of Value, Says Analysis Startup PatentVector

IP Close Up

Frederick Shelton IV, arguably the most prolific and financially successful inventors ever, is a Johnson & Johnson medical device innovator unknown to pretty much everyone Continue reading.